secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001213900-23-037928
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics reports Q1 2023 cash of $4M, Fast Track for tecarfarin
----------------------------------------------------------------------------

- FDA granted Fast Track designation for tecarfarin in ESRD/AFib patients in Jan 2023.
- Completed IPO raising $7.0M gross proceeds; cash at March 31, 2023 was $4.0M.
- Q1 2023 operating expenses (ex-non-cash) were $913,653; cash expected to fund through Q2 2024.
- Plans Phase 3 ACTOR-AF trial (492 patients) as pivotal step before NDA submission.
- Market opportunity for tecarfarin estimated up to $1B annually if FDA approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390023037928/0001213900-23-037928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390023037928/ea178256-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-037928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer